← back to search

Magali Taiel

GenSight Biologics (France) · US
Area of research
Molecular Biology · Ophthalmology
Research interest
Research interests include Retinal Development and Disorders, Mitochondrial Function and Pathology, Retinal Diseases and Treatments, and Photosynthetic Processes and Mechanisms.
h-index
16
citations
1,959
works
49
NIH funding
primary concept
Medicine
email

Recent publications

Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy
JAMA Ophthalmology 2024cited by 18position: middledoi
Meta-analysis of treatment outcomes for patients with m.11778G>A MT-ND4 Leber hereditary optic neuropathy
Survey of Ophthalmology 2024cited by 16position: middledoi
Randomized trial of bilateral gene therapy injection for m.11778G&amp;gt;A <i>MT-ND4</i> Leber optic neuropathy
Brain 2022cited by 77position: middledoi
Indirect Comparison of Lenadogene Nolparvovec Gene Therapy Versus Natural History in Patients with Leber Hereditary Optic Neuropathy Carrying the m.11778G&gt;A MT-ND4 Mutation
Ophthalmology and Therapy 2022cited by 28position: middledoi
Safety of Lenadogene Nolparvovec Gene Therapy Over 5 Years in 189 Patients With Leber Hereditary Optic Neuropathy
American Journal of Ophthalmology 2022cited by 23position: middledoi
Partial recovery of visual function in a blind patient after optogenetic therapy
Nature Medicine 2021cited by 679position: middledoi
Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset
Ophthalmology 2021cited by 162position: middledoi
Natural history of patients with Leber hereditary optic neuropathy—results from the REALITY study
Eye 2021cited by 70position: middledoi
Intravitreal Gene Therapy vs. Natural History in Patients With Leber Hereditary Optic Neuropathy Carrying the m.11778G&gt;A ND4 Mutation: Systematic Review and Indirect Comparison
Frontiers in Neurology 2021cited by 60position: middledoi
Biodistribution of intravitreal lenadogene nolparvovec gene therapy in nonhuman primates
Molecular Therapy — Methods & Clinical Development 2021cited by 38position: middledoi
Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy
Science Translational Medicine 2020cited by 224position: middledoi
Visual Outcomes in Leber Hereditary Optic Neuropathy Patients With the m.11778G&gt;A (MTND4) Mitochondrial DNA Mutation
Journal of Neuro-Ophthalmology 2020cited by 108position: middledoi
Long-Term Follow-Up After Unilateral Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy: The RESTORE Study
Journal of Neuro-Ophthalmology 2020cited by 69position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Nancy J. Newman · Emory University7 papers (2020–2024)José‐Alain Sahel · Centre National de la Recherche Scientifique7 papers (2020–2024)Valério Carelli · Istituto delle Scienze Neurologiche di Bologna7 papers (2020–2024)Patrick Yu‐Wai‐Man · Moorfields Eye Hospital NHS Foundation Trust7 papers (2020–2024)Valérie Biousse · Emory University5 papers (2020–2024) · 4 papers (2020–2022)Alfredo A. Sadun · Doheny Eye Institute4 papers (2020–2022)Thomas Klopstock · Georgetown University4 papers (2020–2022)Robert C. Sergott · Georgetown University4 papers (2020–2022)Mark L. Moster · University of Alabama at Birmingham4 papers (2020–2022) · 3 papers (2020–2021)Laure Blouin · SpineVision (France)3 papers (2020–2021)David J. Calkins · Sandia National Laboratories2 papers (2020–2021)Serge Picaud · Inserm2 papers (2020–2021)Claudia Priglinger · Ludwig-Maximilians-Universität München2 papers (2020–2021) · 2 papers (2021–2022)Rustum Karanjia · University of Ottawa2 papers (2020–2021) · 2 papers (2021–2024) · 1 papers (2020–2020)Jean‐Baptiste de Saint Aubert · Sorbonne Université1 papers (2021–2021)